Drugs / TEV-53408
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06625177 | Nov 2024 → Sep 2026 overdue | vitiligo | Teva Branded Pharmaceutical Products R&D, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06807463 | Mar 2025 → Sep 2026 overdue | celiac disease | Teva Branded Pharmaceutical Products R&D, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA tevapharm.com ↗
Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA tevapharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEV-53408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06625177 ↗ |
| Route | Subcutaneous | “TEV-53408 injection administered subcutaneously” NCT06625177 ↗ |